Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival

A retrospective analysis of 72 patients with JAK2 inhibitor-naïve myelofibrosis and anemia who received momelotinib demonstrated a short-term survival benefit among those who achieved an anemia response. Median survival after momelotinib treatment was 3.2 years, with univariate analysis showing superior survival in anemia responders (median 3.8 vs. 2.8 years; p = .14) and multivariable analysis confirming the benefit in this patient population (p = .02; HR 0.5, 3/5/10-year survival; 69%/38%/25%).